NCT04159415View on ClinicalTrials.gov

Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

January 5, 2022

Study Completion Date

September 24, 2024

Conditions
Generalized Lipodystrophy
Interventions
DRUG

Placebo

Intravenous (IV) infusion loading dose or subcutaneous (SC) injection weekly (QW).

DRUG

Low-Dose REGN4461

IV infusion loading dose or SC injection QW.

DRUG

High-dose REGN4461

IV infusion loading dose or SC injection QW.

Trial Locations (8)

2665

Regeneron Research Site, Piura

20892

Regeneron Research Site, Bethesda

21808

Regeneron Research Site, Diyarbakır

35100

Regeneron Research Site, Izmir

48105

Regeneron Research Site, Ann Arbor

75390

Regeneron Research Site, Dallas

117036

Regeneron Research Site, Moscow

06230

Regeneron Research Site, Ankara

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT04159415 - Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy | Biotech Hunter | Biotech Hunter